$8,000 apiece (both sets were contracted through Knome). I spent the Summer of 2013 in Arlington, MA working on analyzing this genomic data on both Knome's and Ingenuity's Variant Analysis platforms. Fll pull together our existing shareholder list, if you'd like it. You were given 2% of the company's

sequenced the first three genomes for $20,000 apiece, and in 2012 sequenced another 12 genomes for $8,000 apiece (both sets were contracted through Knome). I spent the Summer of 2013 in Arlington, MA working on analyzing this genomic data on both Knome's and Ingenuity's Variant Analysis platforms. Fl

$8,000 apiece (both sets=were contracted through Knome). I spent the Summer of 2013 in Arlington, MA=working on analyzing this genomic data on both Knome's and Ingenuity's Vari=nt Analysis platforms. I'll pull together ou= existing shareholder list, if you'd like it. You were given 2% of the comp=ny's

sequenced the first three genomes for $20,000 a=iece, and in 2012 sequenced another 12 genomes for $8,000 apiece (both sets=were contracted through Knome). I spent the Summer of 2013 in Arlington, MA=working on analyzing this genomic data on both Knome's and Ingenuity's Vari=nt Analysis platforms. I'

.L.R. are uncompensated members of the advisory board for Complete Genomics. H.L.R. is a compensated member of the advisory boards for GenomeQuest, Knome, and Omicia and uncompensated for BioBase and Clinical Future. B.R.K., H.L.R., and M.S.Wi. are involved with clinical laboratories offering genome